Archive

May 7, 2025

Browsing

India’s equity markets experienced a volatile but ultimately resilient session on Wednesday following the announcement of significant military action against Pakistan.

While benchmark indices opened sharply lower in immediate reaction to news of India’s retaliatory strikes, known as ‘Operation Sindoor’, they quickly pared losses, suggesting investors, while watchful, were not panicking about the escalation.

The trading day began under the shadow of heightened geopolitical tensions.

India confirmed early Wednesday that its Armed Forces had launched precision missile strikes targeting nine terrorist sites located in Pakistan and Pakistan-occupied Kashmir (PoK).

This action, codenamed ‘Operation Sindoor’, was explicitly positioned by India as a “precise and restrained response” to the recent deadly terror attack in Pahalgam, designed to be “non-escalatory” and focused solely on “known terror camps” while avoiding civilian or Pakistani military targets – a characterization disputed by Pakistan.

The immediate market reaction was negative, with the Sensex opening 692 points lower at 79,948.80. However, this initial dip proved short-lived.

The index quickly erased these losses and even pushed into positive territory, rising over 200 points to touch 80,845 before settling back into a more volatile, range-bound pattern.

Around 10 AM, the Sensex was down just 32 points (0.04%) at 80,609, while the Nifty 50 was hovering near the flatline, down 19 points (0.08%) at 24,361.

The BSE Midcap index was flat, while the Smallcap index remained down 0.33%, indicating slightly more pressure on smaller stocks.

Expert analysis: measured strike limits market panic

Market experts attributed the relatively contained market reaction, despite the significant military action, to the perceived nature of the strikes.

The focus on terrorist infrastructure, rather than broader military or economic targets, was seen as a key factor in preventing widespread panic.

“What stands out in ‘Operation Sindoor’ from the market perspective is its focused and non-escalatory nature,” VK Vijayakumar, Chief Investment Strategist at Geojit Investments, told Live Mint.

We have to wait and watch how the enemy reacts to these precision strikes by India. The market is unlikely to be impacted by the retaliatory strike by India since that was known and discounted by the market.

The clear messaging that India sought retaliation against terror camps, not broader escalation, appeared to reassure investors.

However, experts acknowledge the potential for further developments.

“There could be some reaction from Pakistan, as it may feel the need to save face,” Vijayakumar added, though he also noted, “Pakistan does not have the economic muscle to sustain a prolonged conflict.”

Historical context: market resilience during past conflicts

History offers some perspective on the Indian market’s behavior during periods of conflict with Pakistan.

Generally, the market has shown remarkable resilience, often supported by the underlying strength of the domestic economy.

During the 1999 Kargil War (May 3 – July 26), the market experienced only a minor decline of 0.8%.

Even during the two days of the Mumbai 26/11 terror attacks in 2008, the Sensex actually climbed roughly 400 points.

While the market did react negatively after the 2019 Pulwama attack (indices dropped over 1.8% between Feb 14 – Mar 1), subsequent actions like the Balakot airstrikes saw varied responses.

“Market responses may be muted during times of Indo-Pak conflict,” Vijayakumar explained.

The domestic market has never panicked during such episodes, as India holds a clear advantage in a conventional war.

Trivesh D, COO of Tradejini, echoed this, pointing out the Sensex surged 37% during the Kargil War period and saw only minor dips post-Pulwama before resuming its uptrend.

“History indicates that corrections are typically mild and quickly rebound,” Rajesh Sinha, Senior Research Analyst at Bonanza Group, told Live Mint.

Investment strategy: focus on quality, avoid panic

Given the current situation, market experts advise investors against panic selling and recommend focusing on quality, particularly in the large-cap space, which tends to offer more stability during volatile periods.

“Even as small-cap and mid-cap segments could lag as a few investors turn defensive amid border tensions, the situation offers a compelling opportunity to be overweight in quality large-cap stocks,” suggested Sinha.

A diversified portfolio approach is recommended. Sinha highlighted sectors like leading banks (with strong capital), FMCG (due to inelastic demand), and potentially defence contractors (on hopes of increased budgets) as areas that might show relative strength.

Trivesh D also suggested keeping an eye on defence and infrastructure, while noting the defensive nature of Pharma and FMCG.

He cautioned against “knee-jerk buying based on fear or news flow,” urging investors to “stay aligned with the broader trend and use any dips to enter quality names.”

Vijayakumar noted that valuations remain elevated (Nifty > 20x FY26 earnings), suggesting “no deep value in any sector.”

However, he still sees bright prospects for financials and potential in telecom, while viewing the defence sector as having received a sentimental boost but lacking deep value currently.

The key takeaway is to remain invested but exercise caution, focusing on fundamentally sound companies.

The post After ‘Operation Sindoor’: what does the market’s volatile swing tell us about investor sentiment? appeared first on Invezz

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Big pharma ETFs

Many of these funds have diverse holdings across some of the most important sectors in the pharmaceutical industry, including pain therapeutics, oncology, vaccines and biotechnology. Data was gathered on May 6, 2025.

1. VanEck Pharmaceutical ETF (NASDAQ:PPH)

Total assets under management: US$653.61 million

Established in late 2011, the VanEck Pharmaceutical ETF tracks the MVIS US Listed Pharmaceutical 25 Index. It has the capacity to provide big returns, even though there are some risks attached to the ETF. An analyst report indicates that investors looking for ‘tactical exposure’ to the pharma sector might consider this ETF as an investment option.

The ETF has 25 holdings, with the top five being Eli Lilly (NYSE:LLY) at a weight of 12.17 percent, AbbVie (NYSE:ABBV) at 6.48 percent, Johnson & Johnson (NYSE:JNJ) at 6.45 percent, Novartis (NYSE:NVS) at 5.43 percent and Cencora (NYSE:COR) at 5.34 percent.

2. iShares US Pharmaceuticals ETF (ARCA:IHE)

Total assets under management: US$571.51 million

Created on May 5, 2006, this iShares ETF tracks some of the top US pharma companies. In total, the iShares US Pharmaceuticals ETF has 41 holdings, with the vast majority being large-cap stocks.

Of its holdings, Eli Lilly and Johnson & Johnson are by far the largest portions in its portfolio, coming in at weightings of 24.55 percent and 23.38 percent, respectively. The next highest are Royalty Pharma (NASDAQ:RPRX) at 4.93 percent, Zoetis (NYSE:ZTS) at 4.80 percent and Viatris (NASDAQ:VTRS) at 4.57 percent.

3. Invesco Pharmaceuticals ETF (ARCA:PJP)

Total assets under management: US$240.1 million

The Invesco Pharmaceuticals ETF is primarily focused on providing exposure to US-based pharma companies. An analyst report states that this ETF chooses individual securities based on certain investment criteria, namely stock valuation and risk factors. Invesco changed the fund’s name from the Invesco Dynamic Pharmaceuticals ETF in August 2023.

This ETF was started on June 23, 2005, and currently tracks 31 companies. Its top holdings are Abbott Laboratories (NYSE:ABT) with a weight of 5.2 percent, AbbVie at 5.17 percent, Johnson & Johnson at 5 percent, Gilead Sciences (NASDAQ:GILD) at 4.94 percent and Eli Lilly at 4.86 percent.

4. SPDR S&P Pharmaceuticals ETF (ARCA:XPH)

Total assets under management: US$139.14 million

The SPDR S&P Pharmaceuticals ETF came into the market on June 19, 2006, and represents the pharmaceutical sub-industry sector of the S&P Total Markets Index. An analyst report for the ETF suggests that due to its narrow focus — which includes pharma giants that post ‘big returns’ during times of consolidation — it should not be considered for a long-term portfolio.

This pharma ETF tracks 43 holdings, with relatively close weighting among its holdings. XPH’s top five holdings are Corcept Therapeutics (NASDAQ:CORT) with a weight of 5.26 percent, Eli Lilly at 3.99 percent, Royalty Pharma (NASDAQ:RPRX) at 3.98 percent, Zoetis at 3.87 percent and Johnson & Johnson at 3.81 percent.

5. KraneShares MSCI All China Health Care Index ETF (ARCA:KURE)

Total assets under management: US$82.86 million

The KraneShares MSCI All China Health Care Index ETF was launched in February 2018 and tracks an index of large- and mid-cap Chinese stocks in the healthcare sector, all weighted by market capitalization. According to an analyst report, the fund provides investors with ‘exposure to a relatively small slice of the Chinese economy.’

The ETF tracks 46 holdings, and its top five are Jiangsu Hengrui Medicine (SHA:600276) at 8.33 percent, BeiGene (OTC Pink:BEIGF,HKEX:6160) at 7.88 percent, Shenzhen Mindray Bio-Medical Electronics (SZSE:300760) at 6.79 percent, Wuxi Biologics (OTC Pink:WXIBF,HKEX:2269) at 6.67 percent and Innovent Biologics (OTC Pink:IVBXF,HKEX:1801) at 5.51 percent .

Securities Disclosure: I, Melissa Pistilli, hold no investment interest in any of the companies mentioned in this article.

Keep reading…Show less
This post appeared first on investingnews.com

U.S. pharmacy chain Rite Aid on Monday filed for bankruptcy protection for the second time in as many years, according to a court filing.

Pharmacy chains, such as Rite Aid, Walgreens and CVS, have been under pressure as falling drug margins and competition from Walmart and Amazon have led to a closure of hundreds of stores.

Walgreens, facing significant losses, recently agreed to a $10 billion buyout by private equity firm Sycamore Partners — a dramatic decline from its $100 billion valuation a decade ago, underscoring the severe challenges facing traditional pharmacy retailers.

Rite Aid used its previous bankruptcy in 2023 to cut $2 billion in debt, close hundreds of stores, sell its pharmacy benefit company, Elixir, and negotiate settlements with its lenders, drug distribution partner McKesson and other creditors.

The previous bankruptcy also resolved hundreds of lawsuits alleging that Rite Aid ignored red flags when filling suspicious prescriptions for addictive opioid pain drugs.

But despite those settlements, Rite Aid still had $2.5 billion in debt when it emerged from bankruptcy as a private company owned by its lenders in 2024.

According to Monday’s court filing, the company has estimated assets and liabilities in the range of $1 billion to $10 billion.

The company was unable to secure additional capital from lenders, which it needed to continue operating the business, Bloomberg News reported earlier in the day, citing an internal letter from CEO Matthew Schroeder to the company’s employees.

The letter also states that the drug store chain intends to reduce its workforce at its corporate offices in Pennsylvania.

Rite Aid operated about 2,000 pharmacies in 2023 but now has only 1,250 stores across the U.S., with recent closures significantly reducing its presence in markets such as Ohio and Michigan.

This post appeared first on NBC NEWS

Secretary of State Marco Rubio is planning to merge the responsibilities of the Palestinian Affairs Office into the U.S. Embassy in Jerusalem in an effort to continue a diplomatic mission in Israel’s capital that was put in place by President Donald Trump during his first term in office.

State Department spokesperson Tammy Bruce announced Rubio’s decision during a press briefing Tuesday.

‘Secretary Rubio has decided to merge the responsibilities of the office of the Palestinian Affairs Office fully into other sections of the United States Embassy in Jerusalem,’ Bruce said. ‘This decision will restore the first Trump-term framework of a unified U.S. diplomatic mission in Israel’s capital that reports to the U.S. ambassador to Israel.’

She added that U.S. Ambassador to Israel Mike Huckabee will begin to make the necessary changes to implement the merger over the coming weeks.

‘The United States remains committed to its historic relationship with Israel, bolstering Israel’s security and securing peace to create a better life for the entire region,’ Bruce said.

The Biden administration established the U.S. Office of Palestinian Affairs in 2022 after reversing Trump’s closure of the consulate to the Palestinians in Jerusalem during his first administration.

Biden’s move was viewed by some as rewarding the Palestinian leadership after a wave of terrorism during which two Palestinians wielding an ax and knife murdered three Israelis in the town of Elad in May 2022.

The first Trump administration helped to negotiate groundbreaking agreements, called the Abraham Accords, in 2020 to normalize diplomatic relations between Israel and the United Arab Emirates, Bahrain, Sudan and Morocco.

The Israeli government vehemently opposed a reopening of the Palestinian consulate in Jerusalem because it would undercut the holy city as the undivided capital of Israel.

The U.S. Jerusalem Embassy Act of 1995 recognizes Jerusalem as the capital of Israel and calls for it to remain an undivided city. 

Trump, in 2017, recognized Jerusalem as Israel’s capital in 2017 and moved the U.S. Embassy from Tel Aviv to Jerusalem the following year.

Fox News’ Benjamin Weinthal contributed to this report.

This post appeared first on FOX NEWS